RA CAPITAL MANAGEMENT, L.P. purchased $292K of ARTV (indirect holdings)
RA CAPITAL MANAGEMENT, L.P. purchased 32,876 indirectly-held shares of Artiva Biotherapeutics, Inc. (ARTV) at an average of $8.89 ($8.88–$8.98, $0.29M total) across 2 trades over 2026-06-25 to 2026-06-26.
How this was made
The 30-second read
Why it matters
The newest concrete fact is the disclosed open-market purchase amount, price range, and post-transaction share count; it may modestly influence sentiment but does not change operating outlook.
Market read
Traders may treat the filing as a small bullish read-through, but without accompanying fundamental updates it is unlikely to drive a sustained repricing.
What to watch
No 10b5-1 plan is cited; however, the filing does not clarify the economic driver of the indirect purchase or whether additional related transactions occurred.
Background
The article is an SEC Form 4 insider transaction disclosure for Artiva Biotherapeutics (ARTV), reported by Ra Capital Management, L.P. as a director/10% owner with an indirect position.
Ticker impact
Artiva Biotherapeutics disclosed a Form 4: Ra Capital Management bought 32,876 shares of ARTV at ~$8.89–$8.98 (indirect) on 6/25–6/26.
Likely limited near-term impact; any effect is more sentiment/positioning than fundamentals.
The filing is primary-source (SEC Form 4) and shows direction (open-market purchase) and size, but it does not include new company performance, guidance, or regulatory/clinical outcomes.
Market effects
Minimal; this is single-name insider/holder activity with no sector-wide datapoint.
None indicated.
None indicated.
Counterpoint
Indirect purchases by a large holder can reflect portfolio rebalancing or planned activity rather than a fresh view on near-term fundamentals.
Key entities
- issuerArtiva Biotherapeutics, Inc.
Subject of the Form 4 insider transaction; shares purchased via indirect holdings.
- insider/10% ownerRA Capital Management, L.P.
Reporter of the Form 4; conducted open-market purchases of ARTV shares on 6/25–6/26.
